Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

IMV Presents Positive Initial Results From The MVP-S Phase 2B VITALIZE Trial

Author: Benzinga Newsdesk | February 13, 2023 08:07am

The company announced positive preliminary data from the VITALIZE Phase 2B trial evaluating its lead DPX product, maveropepimut-S ("MVP-S"), in combination with pembrolizumab in patients with relapsed, refractory Diffuse Large B Cell Lymphoma ("r/r DLBCL").

  • Early analysis reveals clinically meaningful activity in refractory DLBCL patients
  • Multiple confirmed complete responses observed in heavily pre-treated patients
  • No adverse safety and tolerability signal reported, consistent with previous clinical trials

Posted In: IMV


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist